Join
Live feed
·
PRReleasevia Quantisnow
Moderna Inc. logo
PPD, Inc. logo
McKesson Corporation logo

Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

ByQuantisnow·Wall Street's wire, on your screen.
MRNA· Moderna Inc.PPD· PPD, Inc.MCK· McKesson Corporation
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRNA (Moderna Inc.), PPD (PPD, Inc.), MCK (McKesson Corporation) and more on Quantisnow.

Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization | Quantisnow